1. 3009 Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement. (September 2015) Authors: Varga, A.; Camidge, D.R.; Sequist, L.V.; Wakelee, H.; Ou, S.H.; Goldman, J.W.; Papadimitrakopoulou, V.; Gadgeel, S.; Mekhail, T.; Oxnard, G.R.; Socinski, M.; Solomon, B.; Yu, H.; Matheny, S.; Despain, D.; Soria, J.C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S598 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 3088 Efficacy of rociletinib (co-1686) in EGFR-mutant non-small cell lung cancer (NSCLC) patients (pts) assessed with a plasma EGFR test. (September 2015) Authors: Gadgeel, S.; Soria, J.C.; Goldman, J.W.; Wakelee, H.; Camidge, D.R.; Yu, H.; Varga, A.; Solomon, B.; Oxnard, G.R.; Ou, S.H.; Papadimitrakopoulou, V.; Liu, S.V.; Reckamp, K.; Spira, A.; Piotrowska, Z.; Despain, D.; Karlovich, C.; Yurasov, S.; Sequist, L.V. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S628 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 3104 Rociletinib treatment and outcomes in non-small cell lung cancer (NSCLC) patients with negative central testing for T790M. (September 2015) Authors: Solomon, B.; Wakelee, H.; Sequist, L.V.; Gadgeel, S.; Soria, J.C.; Goldman, J.W.; Yu, H.; Camidge, D.R.; Papadimitrakopoulou, V.; Matheny, S.; Despain, D.; Besse, B. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S636 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 3105 Dose optimization of rociletinib for EGFR mutated NSCLC: Benefit/risk analysis from the TIGER-X trial. (September 2015) Authors: Soria, J.C.; Goldman, J.W.; Wakelee, H.; Gadgeel, S.; Camidge, D.R.; Solomon, B.; Yu, H.; Oxnard, G.R.; Ou, S.H.; Papadimitrakopoulou, V.; Perol, M.; Reckamp, K.; Varga, A.; Dziadziuszko, R.; Chouaid, C.; Cortot, A.; Do, P.; Moro-Sibilot, D.; Poudenx, M.; Sequist, L.V. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S637 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 3113 AZD9291 in pre-treated patients with T790M positive advanced non-small cell lung cancer (NSCLC): Pooled analysis from two Phase II studies. (September 2015) Authors: Goss, G.D.; Yang, J.C.H.; Ahn, M.J.; Tsai, C.M.; Bazhenova, L.; Sequist, L.V.; Ramalingam, S.S.; Shepherd, F.A.; Ghiorghiu, S.; Cantarini, M.; Mann, H.; Mitsudomi, T.; Jänne, P.A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S640 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. First-line afatinib for advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials. (February 2017) Authors: Schuler, M.; Paz-Ares, L.; Sequist, L.V.; Tan, E.H.; Mok, T.; Hirsh, V.; O'Byrne, K.; Zhang, L.; Yamamoto, N.; Boyer, M.; Shah, R.; Bennouna, J.; Dickgreber, N.J.; De Grève, J.; Love, J.; Märten, A.; Fan, J.; Ehrnrooth, E.; Park, K.; Yang, J.C.H. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S176 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗